Antibody against Neurofibromin: Diagnostic and Prognostic Marker for Glioma Treatment
Monoclonal Antibody against Neurofibromin as a diagnostic and prognostic Marker for Glioma Treatment. The proof of concept is established with Biopsy Material. The antibody is fast, reliable & ready to use.
Further information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Sorafenib’s Impact: Understanding Muscle Wasting from Chemotherapy
Research team clarifies molecular basis for cachexia Chemotherapeutic agents are often used to treat cancer. They combat tumour growth, but also have a number of undesirable side effects. One of…
Cracking the GABAA Code: Novel Insights into Brain Receptor Structure
Advanced scientific instruments allow scientists to build a map of brain receptors, opening the door to possible novel ways to treat epilepsy and mental disorders Certain proteins found in the…
European XFEL Award Felicitates Oxford’s Patrick Heighway
His work helps to pave the way to major contributions to improvements to the facility, and to data analysis and interpretation by means of theory or modelling. Three excellent posters…